NCT03794180View on ClinicalTrials.gov

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

September 5, 2019

Study Completion Date

September 5, 2019

Conditions
Healthy Adult Subjects
Interventions
DRUG

TJ003234

Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline

DRUG

Placebo

Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline

Trial Locations (1)

21201

Pharmaron, Baltimore

Sponsors
All Listed Sponsors
lead

I-Mab Biopharma US Limited

INDUSTRY